Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
itgb1-pulsed dendritic cell vaccine
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ITGB1-pulsed dendritic cell vaccine is an experimental cell-based immunotherapy being developed by researchers at the University of Michigan. The vaccine consists of dendritic cells that have been loaded (pulsed) with the integrin β1 (ITGB1) protein to induce a targeted immune response. ITGB1 is highly expressed on melanoma cells and melanoma cancer stem cells (CSCs), which are implicated in tumor initiation, progression, and metastasis. By presenting ITGB1 antigens, the vaccine aims to stimulate both T-cell mediated and humoral immunity against these CSC populations. Preclinical studies in mouse melanoma models have demonstrated that the ITGB1-DC vaccine significantly inhibits tumor growth and lung metastases, with enhanced efficacy observed when used in combination with ITGB3-targeted vaccines or immune checkpoint inhibitors such as anti-PD-L1.
- Other names
- Integrin beta 1-pulsed dendritic cell vaccineITGB1-pulsed DC vaccineITGB-1-pulsed DC vaccineITGB 1-pulsed DC vaccine
02
Targets
ITGB1 (Integrin beta-1)
Beyond the preview
Go deeper on itgb1-pulsed dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on itgb1-pulsed dendritic cell vaccine.